Cue Biopharma, Inc.

Stage 3 · Topping · week 4

As of Oct 22, 2026, Cue Biopharma is in Stage 3, the topping phase, now in week 4 (since Oct 1, 2026). It closed at $18.89, 50.1% below its 52-week high and below its 200-day average, which is rising.

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. More about the company

$18.89

-0.32% today

$137M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is CUE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 33w

S4 14w

S4 29w

S2 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 4w → S4 13w → S1 10w → S4 33w → S1 8w → S2 4w → S3 3w → S4 1w → S3 2w → S2 4w → S3 4w → S4 14w → S1 10w → S4 29w → S1 5w → S2 16w → S3 1w → S2 2w → S3 3w current

Total tracked: 164 weeks across 19 stage runs.

CUE among Biotechnology259th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…259	CUECue Biopharma, Inc.	Stage 3 · wk 4	37	−40.4%

vs 52W High

-50.1%

$5.31 lo$37.84 hi

50.1% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 4

1w13w26w

Week 4, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-9.5%

200 DMA: $20.88 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.19x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-40.4%

-41.2%

+13.7%

YTD

+86.8%

-23.7%

Scan Membership

Breakout Watch

Latest: 2025-02-18

10 appearances in last 60 days. First seen: 2019-04-18.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 4 · Vol 0.19x

2026-10-21S3

Wk 3 · Vol 0.34x

2026-10-20S3

Wk 3 · Vol 0.56x

2026-10-19S3

Wk 3 · Vol 0.45x

2026-10-16S3

Wk 3 · Vol 0.36x

2026-10-15S3

Wk 3 · Vol 0.77x

2026-10-14S3

Wk 2 · Vol 0.83x

2026-10-13S3

Wk 2 · Vol 1.03x

2026-10-12S3

Wk 2 · Vol 0.60x

2026-10-09S3

Wk 2 · Vol 1.33x

2026-10-08S3

Wk 2 · Vol 0.37x

2026-10-07S3

Wk 1 · Vol 0.45x

Moving averages & range

50 DMA

$26.54

200 DMA

$20.88

52W High

$37.84

52W Low

$5.31

5D Low

$16.08

Resistance levels (recent highs)

20d High

$31.41

60d High

$37.84

120d High

$37.84

250d High

$37.84

Next resistance

+66.3%

to 20d High

ROE

-1603.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 42.7

Cue Biopharma: quick answers

What stage is Cue Biopharma in?

As of Oct 22, 2026, Cue Biopharma (CUE) is in Stage 3, the topping phase. It entered Stage 3 on Oct 1, 2026 and is in week 4. What the four stages mean

Is Cue Biopharma in an uptrend?

Its uptrend has stalled. Cue Biopharma is in Stage 3, the topping phase that follows an advance. It trades 9.5% below its 200-day average, which is rising.

How far is Cue Biopharma from its 52-week high?

Cue Biopharma closed at $18.89 on Oct 22, 2026, 50.1% below its 52-week high of $37.84. Its 52-week low is $5.31.

How has Cue Biopharma performed over the past year?

As of Oct 22, 2026, Cue Biopharma is down 23.7% over the past year and up 86.8% so far in 2026.

Which sector and industry is Cue Biopharma in?

Cue Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.